Order — ECLI:EU:C:2012:68
Date: 2012-02-09
Language of the case: German
Court formation: Eighth Chamber
Subject matter: Intellectual, industrial and commercial property;Approximation of laws;Patents
Procedure: Reference for a preliminary ruling
Origin: Germany

Reference for a preliminary ruling from the Landgericht Düsseldorf (Germany), lodged on 16 November 2011 - Novartis AG v Actavis Deutschland GmbH & Co KG, Actavis Ltd. (Case C-574/11) Language of the case: German Referring court Landgericht Düsseldorf Parties to the main proceedings Applicant: Novartis AG Defendants: Actavis Deutschland GmbH & Co KG, Actavis Ltd. Question referred Are Articles 4 and 5 of Regulation (EC) No 469/2009  to be interpreted as meaning that the protection conferred by a supplementary protection certificate, which has been granted for a single active ingredient (in this case, Valsartan), extends to a form which contains a combination of active ingredients featuring that single active ingredient (in this case, Valsartan + Hydrochlorothiazide)? ____________ 1 - Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version), OJ 2009 L 152, p. 1.